Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone vs Triamcinolone in Shoulder Calcific Tendinopathy
NCT01652495Phase 4
Key facts
- Status
- Completed
- Start
- Mar 2012
- Primary completion
- May 2013
- Countries
- 1
- Sponsor
- Istituto Ortopedico Rizzoli
- Modality
- Orthosteric Ligands
- Conditions
- Calcific tendinitis of the rotator cuff
01
Overview
Phase 4, randomised trial in Calcific tendinitis of the rotator cuff comparing Methylprednisolone acetate with Triamcinolone acetonide (2 arms). Primary endpoint: Functional Improvement Measured According to Percentage Change in Constant Score at 180 days. Started Mar 2012; status: completed.
02
Design
2 arms- Study design
- Randomized
Methylprednisolone acetate
Single injection of 40 mg methylprednisolone acetate
Triamcinolone acetonide
Single injection of 40 mg triamcinolone acetonide
03
Who it enrols
Patients with painful rotator cuff calcific tendonitis. Excludes patients with diabetes, glaucoma, coagulopathies, systemic chronic inflammatory diseases, or recent corticosteroid use.
04
Endpoints
Primary
Functional Improvement Measured According to Percentage Change in Constant Score
Secondary
Percentage of Patients With Suppression of Hypothalamus-pituitary-adrenal Axis
Reduction of Pain Severity Expressed as Percentage Change in VAS Score
Beyond the preview
Go deeper on NCT01652495.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01652495.